Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Background In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated the effica...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Yoshino, Takayuki, Komatsu, Yoshito, Yamada, Yasuhide, Yamazaki, Kentaro, Tsuji, Akihito, Ura, Takashi, Grothey, Axel, Van Cutsem, Eric, Wagner, Andrea, Cihon, Frank, Hamada, Yoko, Ohtsu, Atsushi
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2014
Matèries:
Phase III Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434855/
https://ncbi.nlm.nih.gov/pubmed/25213161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0154-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars